A rapamycin-loading platelet membrane hybrid liposome with anti-inflammation effect and long-lasting repair capability for acute kidney injury
Journal of Controlled Release · 2025-04 · 380 · 927-942
DOI: 10.1016/j.jconrel.2025.02.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2025-04. Verfasst von Miaomiao Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Infectious Disease and Biosecurity, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery Ministry of Ed…. Hauptthemen laut MEDLINE: Sirolimus, Acute Kidney Injury, Blood Platelets, Anti-Inflammatory Agents. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Acute kidney injury (AKI) represents a rapid decline in kidney function, often associated with significant morbidity and mortality. Inefficient management of acute-phase inflammation and inadequate repair of established damage exacerbate AKI and facilitate its progression to chronic kidney disease (CKD). Platelet membrane (PM) has emerged as a promising targeting ligand in various studies. PM proteins can also facilitate the recruitment and differentiation of CD34+ cells (hematopoietic stem cells and endothelial progenitor cells) through both direct and indirect mechanisms, including enhancing adhesion of CD34+ cells to damaged tissues and elevating stromal cell-derived factor-1 (SDF-1) levels in ischemia-reperfusion injury (IRI) kidneys. In parallel, extensive research has demonstrated that rapamycin shows high potential as an anti-inflammatory therapy for AKI. Herein, we design a PM hybrid rapamycin liposome (Rapa@PM-Lipo), which not only improves the delivery efficiency of rapamycin, but also leverages the potential of PM to achieve long-lasting repair. Rapa@PM-Lipo significantly reduced Acute renal Tubular Necrosis (ATN) score in IRI kidneys following intravenous administration, both as a single and multiple doses. This study exploits the therapeutic potential of PM and explores its novel applications for facilitating tissue repair, presenting a promising strategy for the treatment of AKI and mitigating its progression to CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Institute of Infectious Disease and Biosecurity, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery Ministry of Education, Shanghai, China.
- School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong.
- Department of Cardiology, Huashan Hospital, Fudan University, Shanghai 200040, China. Electronic address: junjie112@163.com.
- Shanghai Institute of Infectious Disease and Biosecurity, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery Ministry of Education, Shanghai, China; Department of Advanced Formulations, Quzhou…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, M., Li, Y., Xu, T., Liu, B., Liu, Y., Cheng, X., Pan, J., & Wang, J. (2025). A rapamycin-loading platelet membrane hybrid liposome with anti-inflammation effect and long-lasting repair capability for acute kidney injury. Journal of Controlled Release, 380, 927-942. https://doi.org/10.1016/j.jconrel.2025.02.012
Vancouver
Zhang M, Li Y, Xu T, Liu B, Liu Y, Cheng X, et al. A rapamycin-loading platelet membrane hybrid liposome with anti-inflammation effect and long-lasting repair capability for acute kidney injury. Journal of Controlled Release. 2025;380:927-942. doi:10.1016/j.jconrel.2025.02.012
BibTeX
@article{Zhang2025,
author = {Zhang, Miaomiao and Li, Yang and Xu, Tongyang and Liu, Botao and Liu, Yue and Cheng, Xu and Pan, Junjie and Wang, Jianxin},
title = {A rapamycin-loading platelet membrane hybrid liposome with anti-inflammation effect and long-lasting repair capability for acute kidney injury},
journal = {Journal of Controlled Release},
year = {2025},
volume = {380},
pages = {927--942},
doi = {10.1016/j.jconrel.2025.02.012}
}
EUVIMED